Even with the recent weakness in the market, there is no surfeit of cheap pharma stocks. Maybe it's not so surprising that Sanofi (NYSE: SNY )
, a company which has taken a different path than most of its Big
Pharma peers, stands out as an exception. Sanofi has not concentrated so
keenly on the oncology or anti-inflammatory spaces, and the company has
a sizable direct presence in many emerging markets.
While Sanofi's guidance for 2014 was both disappointing and short on
details, I think these shares are worth consideration. Strong franchises
in diabetes, rare diseases, and vaccines generate good cash flow, and a
broad pipeline gives the company a more diversified business mix. My
growth expectations are higher than for most pharma companies, but I
believe the shares ought to trade in the $50's today.
Continue here:
Sanofi SA Looks Like One Of The Better Bargains In Big Pharma
No comments:
Post a Comment